TANDEM DIABETES CARE INC: BALYASNY ASSET MANAGEMENT L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. disclosed a stake of more than 5% in Tandem Diabetes Care Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005059). The filing signals that the hedge fund has crossed the 5% passive-investment threshold in the diabetes device maker, making it a notable institutional holder. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further 13G/13D amendments to see whether Balyasny's position is passive or activist in nature.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Balyasny Asset Management L.P., Tandem Diabetes Care Inc